公开(公告)号：US20240318255A1

公开(公告)日：2024-09-26

申请号：US18260011

申请日：2021-12-29

Applicant: Belgian Volition SRL (BE/BE)

Inventor： Jacob Vincent MICALLEF ,  Mark Edward ECCLESTON ,  Marielle HERZOG

IPC: C12Q1/6886 ,  G01N33/53 ,  G01N33/68

CPC classification number: C12Q1/6886 ,  G01N33/5308 ,  G01N33/6854 ,  G01N33/6875

Abstract: The invention relates to methods for detecting disease in a subject by means of a minimally invasive body fluid test for non-nucleosomal cell free DNA fragments. The invention also relates to the measurement or detection of circulating cell free DNA fragments that include a transcription factor binding site sequence as an indicator of the presence of disease in a subject.

公开(公告)号：US20240044913A1

公开(公告)日：2024-02-08

申请号：US18253768

申请日：2021-11-25

Applicant: Belgian Volition SRL (BE/BE)

Inventor： Guillaume ROMMELAERE ,  Mhammed BOUGOUSSA ,  Heather WILSON-ROBLES ,  Marielle HERZOG

IPC: G01N33/68 ,  G01N33/574 ,  G01N1/40

CPC classification number: G01N33/6875 ,  G01N33/57484 ,  G01N1/4077

Abstract: The invention relates to methods for detecting or measuring a cell free nucleoprotein chromatin fragment in a serum or plasma sample involving centrifugation prior to analysis.

公开(公告)号：US20240019432A1

公开(公告)日：2024-01-18

申请号：US18256191

申请日：2021-12-08

Applicant: Belgian Volition SRL (BE/BE)

Inventor： Jason Bradley TERRELL ,  Jacob Vincent MICALLEF ,  Mark Edward ECCLESTON ,  Marielle HERZOG

IPC: G01N33/564

CPC classification number: G01N33/564

Abstract: The invention relates methods for diagnosing patients with multiple sclerosis by detecting cell free nucleosomes as biomarkers in body fluid samples.

公开(公告)号：US20240318226A1

公开(公告)日：2024-09-26

申请号：US18260018

申请日：2021-12-29

Applicant: Belgian Volition SRL (BE/BE)

Inventor： Jacob Vincent MICALLEF ,  Mark Edward ECCLESTON ,  Dorian Fernand François PAMART ,  Marielle HERZOG

IPC: C12Q1/6804 ,  C12Q1/6806 ,  C12Q1/6886

CPC classification number: C12Q1/6804 ,  C12Q1/6806 ,  C12Q1/6886 ,  G01N2800/52

Abstract: The invention relates to methods for detecting disease in a subject by means of a minimally invasive body fluid test for the detection of circulating chromatin fragments that include a transcription factor and associated DNA sequence as an indicator of the presence of disease in the subject, e.g. cancer. The methods may comprise sequencing the associated DNA sequence and/or removing cell free nucleosomes from the body fluid.